Nestlé Health Science plots next steps for C. diff drug Vowst after robust uptake
After a better-than-expected launch, Nestlé Health Science is planning its next commercialization moves for Vowst, an oral pill to treat recurring Clostridioides difficile, or …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
